Intravacc is today touting positive pre-clinical results of its SARS-CoV-2 nasal spray vaccine candidate in non-human subjects.
Bilthoven, Netherlands-based Intravacc’s SARS-CoV-2 outer membrane vesicle (OMV)-based recombinant spike protein (rSp) nasal spray candidate was observed in four groups of mice and four groups of hamsters, all of which received two intranasal immunizations on day one and day 21, according to a news release.
Get the full story at our sister site, Drug Delivery Business News.
Filed Under: clinical trials, Drug Delivery, Drug Discovery, Drug Discovery and Development, Infectious Disease
